ArticleFrontiers in endocrinology2022
Pharmacologic management of weight regain following bariatric surgery.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.Obesity surgery · 2025Pooled it
- Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.Obesity surgery · 2026Observational
- Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery.Cureus · 2026Review
- Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.Acta diabetologica · 2026Review
- Refining the Bariatric Journey: A Proposed Neoadjuvant and Adjuvant Framework for GLP-1 Receptor Agonists Inspired by Oncology.Current obesity reports · 2026Review
- Recurrent Weight Gain after Metabolic Bariatric Surgery (MBS): Emerging Insights on Kidney Function.Obesity surgery · 2026Review
- Efficacy and safety of limb distalization after Roux-en-Y gastric bypass: a retrospective cohort study.Frontiers in surgery · 2026Article
- Clinical Significance of Early Postoperative Weight Loss in Bariatric Surgery: A Narrative Review.Journal of metabolic and bariatric surgery · 2025Review
- Obesity Management Medications as Adjuncts to Metabolic and Bariatric Surgery: Consensus Recommendations from India.Obesity surgery · 2025Review
- Ring Augmentation of the Roux-en-Y Gastric Bypass: A Propensity Score Matched Analysis of 5-Year Follow-Up Results.Obesity surgery · 2025Article
- Assessment and medical management of weight regain after adolescent metabolic and bariatric surgery: a narrative review.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2025Review
- Weight Loss Pharmacotherapy: Current and Future Therapies.Gastrointestinal endoscopy clinics of North America · 2024Review
- Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings.Obesity pillars · 2024Article
- Approach to Obesity Treatment in Primary Care: A Review.JAMA internal medicine · 2024 · on this mapReview
- Adjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review.Current obesity reports · 2024Article
- EndoBridge 2023: highlights and pearls.Hormones (Athens, Greece) · 2024Article
- Special considerations for the adolescent with obesity: An obesity medicine association (OMA) clinical practice statement (CPS) 2024.Obesity pillars · 2024Article
- Semaglutide for weight loss: unanswered questions.Frontiers in endocrinology · 2024Article
- Challenges in the care and treatment of patients with extreme obesity.Archives of endocrinology and metabolism · 2024Review
- Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While bariatric surgery restults in significant long-term weight loss for most patients with obesity, post-surgical weight gain affects a considerable percentage of patients to varying degrees of severity. Furthermore, a small but significant percentage of patients experience inadequate post-surgical weight loss. Although many studies have examined the role of anti-obesity medications to address post-operative weight regain, an evidence-based consensus has not yet been achieved because of the heterogeneity of populations studied and the studies themselves. Observational studies in the post-bariatric surgery population consistently demonstrate the benefit of medical weight management after bariatric surgery, with most evidence highlighting liraglutide, topiramate, and phentermine/topiramate. New anti-obesity medications are anticipated to be helpful for post-surgical weight optimization given their efficacy in the non-surgical population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.